Pulmonary Vascular Biology Laboratory

The focus of the Pulmonary Vascular Biology Lab, led by Dr. Jason Elinoff, is the interplay between lung vascular endothelium and immune effector cells and their contributions to the development and progression of pulmonary arterial hypertension (PAH).

On This Page
Jason Elinoff, M.D.

Senior Investigator Research Interests

Research Interests

Pulmonary arterial hypertension (PAH) is characterized by dysregulated cell proliferation and infiltration of activated inflammatory cells leading to progressive narrowing and obliteration of the distal pulmonary arteries. While current therapeutics reduce pulmonary arterial pressure and increase time to death or transplant, median survival remains only 5-7 years from diagnosis. Unlike selective pulmonary vasodilators alone, approaches directed at inflammatory vascular remodeling have the potential to arrest or even reverse the disease. The focus of the Pulmonary Vascular Biology Lab, led by Dr. Jason Elinoff, is the interplay between lung vascular endothelium and immune effector cells and their contributions to the development and progression of PAH. Current work includes in vitro profiling of human pulmonary artery endothelial cells with heterogeneous PAH-associated molecular defects in order to investigate molecular mechanisms that can exploited therapeutically. The overarching goal of the program is to translate basic science and pre-clinical studies to early phase therapeutic trials in PAH patients.

Featured Publications

Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.

Authors: Lu M, Chen LY, Gairhe S, Mazer AJ, Anderson SA, Nelson JNH, Noguchi A, Siddique MAS, Dougherty EJ, Zou Y, Johnston KA, Yu ZX, Wang H, Wang S, Sun J, Solomon SB, Vanderpool RR, Solomon MA, Danner RL, Elinoff JM.
Am J Physiol Lung Cell Mol Physiol 2022 Mar 01;322(3):L315-L332
Read Publication

Type I Interferon Activation and Endothelial Dysfunction in Caveolin-1 Insufficiency-associated Pulmonary Arterial Hypertension.

Authors: 2. Gairhe S, Awad KS, Dougherty EJ, Ferreyra GA, Wang S, Yu ZX, Takeda K, Demirkale CY, Torabi-Parizi P, Austin ED, Elinoff JM, Danner RL.
Proc Natl Acad Sci USA. 2021 Mar 16;118(11):
Read Publication

Meta-analysis of blood genome-wide expression profiling studies in pulmonary arterial hypertension.

Authors: 3. Elinoff JM, Mazer AJ, Cai R, Lu M, Graninger G, Harper B, Ferreyra GA, Sun J, Solomon MA, Danner RL.
Am J Physiol Lung Cell Mol Physiol. 2020 Jan 01;318(1):L98-L111.
Read Publication

Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg.

Authors: Elinoff JM, Agarwal R, Barnett CF, Benza RL, Rosenzweig EB, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.
Am J Respir Crit Care Med. 2018 Jul 15;198(2):166-174
Read Publication

Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling

Authors: Elinoff JM, Chen LY, Dougherty EJ, Awad KS, Wang S, Biancotto A, Siddiqui AH, Weir NA, Cai R, Sun J, Preston IR, Solomon MA, Danner RL
Cardiovasc Res. 2018 Jan 01;114(1):65-76
Read Publication
View More Publications

Meet the Team

Jason Elinoff, M.D.

Jason Elinoff, M.D.

Tenure Track Investigator

Dr. Elinoff earned his undergraduate degree in Chemistry from Princeton University and his degree in Medicine from the University of Chicago Pritzker School of Medicine. He went on to complete internship and residency training in Internal Medicine at the Massachusetts General Hospital. Dr. Elinoff completed his fellowship training in Critical Care Medicine at the NIH Clinical Center and Pulmonary and Critical Care Medicine at Johns Hopkins University.